{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:06:36Z","timestamp":1788908796682,"version":"build-2803163510"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01843-1","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:11:50Z","timestamp":1788905510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-7266","authenticated-orcid":false,"given":"Jiacheng","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhu","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"1843_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Signal Transduct Target Ther"},{"key":"1843_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641\u201361. https:\/\/doi.org\/10.1038\/s41573-023-00709-2.","journal-title":"Nat Rev Drug Discov"},{"key":"1843_CR3","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo R, Tarantino P, Rich JR, de LoRusso PM. The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development. Cancer Discov. 2024;14:2089\u2013108. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0708.","journal-title":"Cancer Discov"},{"key":"1843_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23:301\u201319. https:\/\/doi.org\/10.1038\/s41573-024-00896-6.","journal-title":"Nat Rev Drug Discov"},{"key":"1843_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","volume":"21","author":"ME Goebeler","year":"2024","unstructured":"Goebeler ME, Stuhler G, Bargou R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat Rev Clin Oncol. 2024;21:539\u201360. https:\/\/doi.org\/10.1038\/s41571-024-00905-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"1843_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1.","journal-title":"Nat Rev Drug Discov.<br>"},{"key":"1843_CR7","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(18)30576-X.","journal-title":"Lancet Oncol"},{"key":"1843_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321. https:\/\/doi.org\/10.1016\/S1470-2045(19)30788-0.","journal-title":"Lancet Oncol"},{"key":"1843_CR9","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles PH, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"key":"1843_CR10","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29:2570\u20136. https:\/\/doi.org\/10.1038\/s41591-023-02589-w.","journal-title":"Nat Med"},{"key":"1843_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-024-01611-z","volume":"17","author":"D Zhou","year":"2024","unstructured":"Zhou D, Wang Y, Chen C, Li Z, Xu K, Zhao K. Targeting GPRC5D for multiple myeloma therapy. J Hematol Oncol. 2024;17:88. https:\/\/doi.org\/10.1186\/s13045-024-01611-z.","journal-title":"J Hematol Oncol"},{"key":"1843_CR12","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1182\/blood.2025029360","volume":"146","author":"A Chari","year":"2025","unstructured":"Chari A, van de Dholaria DN, Weisel B, Mateos K, Goldschmidt MV. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025;146:2902\u201313. https:\/\/doi.org\/10.1182\/blood.2025029360.","journal-title":"Blood"},{"key":"1843_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04522-3","author":"AD Cohen","year":"2026","unstructured":"Cohen AD, Richter J, Trudel S, Lesokhin A, Laubach JP, Thomas SK, et al. FcRH5xCD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. Nat Med [Internet]. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04522-3.","journal-title":"Nat Med [Internet]"},{"key":"1843_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood.2023023419","volume":"144","author":"J Kim","year":"2024","unstructured":"Kim J, Cho J, Lee MH, Yoon SE, Kim WS, Kim SJ. CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis. Blood. 2024;144:629\u201338. https:\/\/doi.org\/10.1182\/blood.2023023419.","journal-title":"Blood"},{"key":"1843_CR15","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood.2020007512","volume":"137","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O\u2019Connor OA, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137:2634\u201345. https:\/\/doi.org\/10.1182\/blood.2020007512.","journal-title":"Blood"},{"key":"1843_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22:790\u2013800. https:\/\/doi.org\/10.1016\/S1470-2045(21)00139-X.","journal-title":"Lancet Oncol"},{"key":"1843_CR17","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","volume":"20","author":"H Tilly","year":"2019","unstructured":"Tilly H, Morschhauser F, Bartlett NL, Mehta A, Salles G, Haioun C, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019;20:998\u20131010. https:\/\/doi.org\/10.1016\/S1470-2045(19)30091-9.","journal-title":"Lancet Oncol"},{"key":"1843_CR18","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1182\/blood.2022017734","volume":"141","author":"Y Song","year":"2023","unstructured":"Song Y, Tilly H, Rai S, Zhang H, Jin J, Goto H, et al. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. Blood. 2023;141:1971\u201381. https:\/\/doi.org\/10.1182\/blood.2022017734.","journal-title":"Blood"},{"key":"1843_CR19","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(22)00335-7.","journal-title":"Lancet Oncol"},{"key":"1843_CR20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.2024025454","volume":"145","author":"LH Sehn","year":"2025","unstructured":"Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after >\/=2 prior therapies. Blood. 2025;145:708\u201319. https:\/\/doi.org\/10.1182\/blood.2024025454.","journal-title":"Blood"},{"key":"1843_CR21","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1182\/blood.2024026830","volume":"145","author":"JD Brody","year":"2025","unstructured":"Brody JD, Jorgensen J, Belada D, Costello R, Trneny M, Vitolo U, et al. Epcoritamab plus GemOx in transplant-ineligible relapsed\/refractory DLBCL: results from the EPCORE NHL-2 trial. Blood. 2025;145:1621\u201331. https:\/\/doi.org\/10.1182\/blood.2024026830.","journal-title":"Blood"},{"key":"1843_CR22","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s43018-025-00941-2","volume":"6","author":"G Cartron","year":"2025","unstructured":"Cartron G, Houot R, Al TY, Le BF, Ysebaert L, Choquet S, et al. Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study. Nat Cancer. 2025;6:1173\u201383. https:\/\/doi.org\/10.1038\/s43018-025-00941-2.","journal-title":"Nat Cancer"},{"key":"1843_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","volume":"30","author":"LE Budde","year":"2024","unstructured":"Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, et al. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial. Nat Med. 2024;30:229\u201339. https:\/\/doi.org\/10.1038\/s41591-023-02726-5.","journal-title":"Nat Med"},{"key":"1843_CR24","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131:1183\u201394. https:\/\/doi.org\/10.1182\/blood-2017-10-811224.","journal-title":"Blood"},{"key":"1843_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood.2019003127","volume":"135","author":"DJ Straus","year":"2020","unstructured":"Straus DJ, Dlugosz-Danecka M, Alekseev S, Illes A, Picardi M, Lech-Maranda E, et al. Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020;135:735\u201342. https:\/\/doi.org\/10.1182\/blood.2019003127.","journal-title":"Blood"},{"key":"1843_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood.2020009178","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021;138:427\u201338. https:\/\/doi.org\/10.1182\/blood.2020009178.","journal-title":"Blood"},{"key":"1843_CR27","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1158\/2159-8290.CD-NB2022-0043","volume":"12","author":"T-DXd","year":"2022","unstructured":"T-DXd. New Standard for HER2-Low Breast Cancer. Cancer Discov. 2022;12:1828. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2022-0043.","journal-title":"Cancer Discov"},{"key":"1843_CR28","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","volume":"31","author":"S Modi","year":"2025","unstructured":"Modi S, Jacot W, Iwata H, Park YH, Vidal LM, Li W, et al. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nat Med. 2025;31:4205\u201313. https:\/\/doi.org\/10.1038\/s41591-025-03981-4.","journal-title":"Nat Med"},{"key":"1843_CR29","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28:1840\u20137. https:\/\/doi.org\/10.1038\/s41591-022-01935-8.","journal-title":"Nat Med"},{"key":"1843_CR30","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med. 2024;30:3717\u201327. https:\/\/doi.org\/10.1038\/s41591-024-03261-7.","journal-title":"Nat Med"},{"key":"1843_CR31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","volume":"20","author":"K Shitara","year":"2019","unstructured":"Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20:827\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(19)30088-9.","journal-title":"Lancet Oncol"},{"key":"1843_CR32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","volume":"22","author":"S Siena","year":"2021","unstructured":"Siena S, Di BM, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22:779\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(21)00086-3.","journal-title":"Lancet Oncol"},{"key":"1843_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","volume":"25","author":"BT Li","year":"2024","unstructured":"Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, et al. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol. 2024;25:707\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(24)00140-2.","journal-title":"Lancet Oncol"},{"key":"1843_CR34","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","volume":"25","author":"K Raghav","year":"2024","unstructured":"Raghav K, Siena S, Takashima A, Kato T, Van den EM, Pietrantonio F, et al. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25:1147\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(24)00380-2.","journal-title":"Lancet Oncol"},{"key":"1843_CR35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","volume":"22","author":"RL Coleman","year":"2021","unstructured":"Coleman RL, Lorusso D, Gennigens C, Gonzalez-Martin A, Randall L, Cibula D, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:609\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(21)00056-5.","journal-title":"Lancet Oncol"},{"key":"1843_CR36","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","volume":"22","author":"EY Yu","year":"2021","unstructured":"Yu EY, Petrylak DP, O\u2019Donnell PH, Lee JL, van der Loriot HM. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2013201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:872\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(21)00094-2.","journal-title":"Lancet Oncol"},{"key":"1843_CR37","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","volume":"30","author":"B Xu","year":"2024","unstructured":"Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, et al. Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial. Nat Med. 2024;30:3709\u201316. https:\/\/doi.org\/10.1038\/s41591-024-03269-z.","journal-title":"Nat Med"},{"key":"1843_CR38","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","volume":"29","author":"BC Cho","year":"2023","unstructured":"Cho BC, Kim DW, Spira AI, Gomez JE, Haura EB, Kim SW, et al. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial. Nat Med. 2023;29:2577\u201385. https:\/\/doi.org\/10.1038\/s41591-023-02554-7.","journal-title":"Nat Med"},{"key":"1843_CR39","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","volume":"24","author":"X Gao","year":"2023","unstructured":"Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial. Lancet Oncol. 2023;24:1134\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(23)00411-4.","journal-title":"Lancet Oncol"},{"key":"1843_CR40","doi-asserted-by":"publisher","first-page":"101242","DOI":"10.1016\/j.xcrm.2023.101242","volume":"4","author":"S Frentzas","year":"2023","unstructured":"Frentzas S, Gan HK, Cosman R, Coward J, Tran B, Millward M, et al. A phase 1a\/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors. Cell Rep Med. 2023;4:101242. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101242.","journal-title":"Cell Rep Med"},{"key":"1843_CR41","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","volume":"31","author":"L Shen","year":"2025","unstructured":"Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025;31:1163\u201370. https:\/\/doi.org\/10.1038\/s41591-024-03450-4.","journal-title":"Nat Med"},{"key":"1843_CR42","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","volume":"23","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022;23:1558\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(22)00621-0.","journal-title":"Lancet Oncol"},{"key":"1843_CR43","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","volume":"24","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24:772\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(23)00242-5.","journal-title":"Lancet Oncol"},{"key":"1843_CR44","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S1470-2045(25)00287-6","volume":"26","author":"E Elimova","year":"2025","unstructured":"Elimova E, Ajani J, Burris H, Denlinger CS, Iqbal S, Kang YK, et al. Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study. Lancet Oncol. 2025;26:847\u201359. https:\/\/doi.org\/10.1016\/S1470-2045(25)00287-6.","journal-title":"Lancet Oncol"},{"key":"1843_CR45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","volume":"16","author":"CM Rudin","year":"2023","unstructured":"Rudin CM, Reck M, Johnson ML, Blackhall F, Hann CL, Yang JC, et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16:66. https:\/\/doi.org\/10.1186\/s13045-023-01464-y.","journal-title":"J Hematol Oncol"},{"key":"1843_CR46","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","volume":"26","author":"KG Paulson","year":"2025","unstructured":"Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, Hafliger S, et al. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol. 2025;26:1300\u201311. https:\/\/doi.org\/10.1016\/S1470-2045(25)00480-2.","journal-title":"Lancet Oncol"},{"key":"1843_CR47","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Terpos E, van de Mateos DN, Moreau MV, Dimopoulos P. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24:e255\u201369. https:\/\/doi.org\/10.1016\/S1470-2045(23)00159-6.","journal-title":"Lancet Oncol"},{"key":"1843_CR48","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","volume":"20","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023;20:558\u201376. https:\/\/doi.org\/10.1038\/s41571-023-00783-w.","journal-title":"Nat Rev Clin Oncol"},{"key":"1843_CR49","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, Usmani S, Cohen AD, van de Leleu DN, Gallego X. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25:e205\u201316. https:\/\/doi.org\/10.1016\/S1470-2045(24)00043-3.","journal-title":"Lancet Oncol"},{"key":"1843_CR50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","volume":"18","author":"K Zhou","year":"2025","unstructured":"Zhou K, Liu X, Zhu H. Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies. J Hematol Oncol. 2025;18:96. https:\/\/doi.org\/10.1186\/s13045-025-01752-9.","journal-title":"J Hematol Oncol"},{"key":"1843_CR51","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41591-025-04175-8","volume":"32","author":"H Lee","year":"2026","unstructured":"Lee H, Ahn S, Gonzales GA, Leblay N, Barakat E, Greening D, et al. Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma. Nat Med. 2026;32:964\u201377. https:\/\/doi.org\/10.1038\/s41591-025-04175-8.","journal-title":"Nat Med"},{"key":"1843_CR52","doi-asserted-by":"publisher","first-page":"101031","DOI":"10.1016\/j.medj.2026.101031","volume":"7","author":"A Muth","year":"2026","unstructured":"Muth A, Holzem A, Neumann AS, Buecklein VL, Subklewe M, Philipp N. T cell exhaustion in bi- and trispecific T cell engager therapy in hematologic malignancies: Mechanisms and implications. Med. 2026;7:101031. https:\/\/doi.org\/10.1016\/j.medj.2026.101031.","journal-title":"Med"},{"key":"1843_CR53","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, et al. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood. 2024;144:615\u201328. https:\/\/doi.org\/10.1182\/blood.2023022823.","journal-title":"Blood"},{"key":"1843_CR54","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1182\/blood.2024025772","volume":"145","author":"CS Lewis","year":"2025","unstructured":"Lewis CS, Barraclough A, Hawkes EA. Emerging biomarkers for CD3xCD20 bispecific antibodies in lymphoma. Blood. 2025;145:1850\u20137. https:\/\/doi.org\/10.1182\/blood.2024025772.","journal-title":"Blood"},{"key":"1843_CR55","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.ccell.2025.09.012","volume":"43","author":"J Zhong","year":"2025","unstructured":"Zhong J, Wu L, Song Z, Xing N, Cui J, Li X, et al. TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study. Cancer Cell. 2025;43:2268\u2013e22813. https:\/\/doi.org\/10.1016\/j.ccell.2025.09.012.","journal-title":"Cancer Cell"},{"key":"1843_CR56","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood.2024025699","volume":"145","author":"G Iacoboni","year":"2025","unstructured":"Iacoboni G, Morschhauser F. Building the future management of follicular lymphoma with T-cell-redirecting strategies. Blood. 2025;145:170\u20135. https:\/\/doi.org\/10.1182\/blood.2024025699.","journal-title":"Blood"},{"key":"1843_CR57","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood.2025030859","volume":"147","author":"M Kamdar","year":"2026","unstructured":"Kamdar M, Bartlett NL. From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma. Blood. 2026;147:2879\u201394. https:\/\/doi.org\/10.1182\/blood.2025030859.","journal-title":"Blood"},{"key":"1843_CR58","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele F, Deluche E, Lusque A, Le BL, Filleron T, Pradat Y, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023;29:2110\u201320. https:\/\/doi.org\/10.1038\/s41591-023-02478-2.","journal-title":"Nat Med"},{"key":"1843_CR59","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cortes","year":"2024","unstructured":"Cortes J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. 2024;30:2208\u201315. https:\/\/doi.org\/10.1038\/s41591-024-03021-7.","journal-title":"Nat Med"},{"key":"1843_CR60","doi-asserted-by":"publisher","first-page":"100502","DOI":"10.1016\/j.medj.2024.08.001","volume":"6","author":"BM Vaz","year":"2025","unstructured":"Vaz BM, Perez-Garcia JM, Garrigos L, Garcia-Saenz JA, Cortez P, Racca F, et al. The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis. Med. 2025;6:100502. https:\/\/doi.org\/10.1016\/j.medj.2024.08.001.","journal-title":"Med"},{"key":"1843_CR61","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat Med. 2024;30:1933\u201342. https:\/\/doi.org\/10.1038\/s41591-024-02992-x.","journal-title":"Nat Med"},{"key":"1843_CR62","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"CE Van","year":"2023","unstructured":"Van CE, di Smyth BM, Chau E, Park I, Siena H. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24:744\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(23)00215-2.","journal-title":"Lancet Oncol"},{"key":"1843_CR63","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","volume":"25","author":"EF Smit","year":"2024","unstructured":"Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares RL, et al. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 2024;25:439\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(24)00064-0.","journal-title":"Lancet Oncol"},{"key":"1843_CR64","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1470-2045(25)00012-9","volume":"26","author":"Z Li","year":"2025","unstructured":"Li Z, Wang Y, Sun Y, Wang L, Li X, Sun L, et al. Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study. Lancet Oncol. 2025;26:437\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(25)00012-9.","journal-title":"Lancet Oncol"},{"key":"1843_CR65","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-026-02612-9","volume":"11","author":"H Yao","year":"2026","unstructured":"Yao H, Yan M, Tong Z, Wu X, Yin Y, Ryu MH, et al. SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial. Signal Transduct Target Ther. 2026;11:104. https:\/\/doi.org\/10.1038\/s41392-026-02612-9.","journal-title":"Signal Transduct Target Ther"},{"key":"1843_CR66","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2025.03.017","volume":"43","author":"D Ma","year":"2025","unstructured":"Ma D, Dai LJ, Wu XR, Liu CL, Zhao S, Zhang H, et al. Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. Cancer Cell. 2025;43:1061\u2013e10757. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.017.","journal-title":"Cancer Cell"},{"key":"1843_CR67","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-025-02149-3","volume":"10","author":"X Hu","year":"2025","unstructured":"Hu X, Zhang Q, Wang L, Zhang J, Ouyang Q, Wang X, et al. ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer. Signal Transduct Target Ther. 2025;10:56. https:\/\/doi.org\/10.1038\/s41392-025-02149-3.","journal-title":"Signal Transduct Target Ther"},{"key":"1843_CR68","doi-asserted-by":"publisher","first-page":"100814","DOI":"10.1016\/j.xcrm.2022.100814","volume":"3","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Qiu MZ, Wang JF, Zhang YQ, Shen A, Yuan XL, et al. Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. Cell Rep Med. 2022;3:100814. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100814.","journal-title":"Cell Rep Med"},{"key":"1843_CR69","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41571-025-01016-y","volume":"22","author":"CJ Robbins","year":"2025","unstructured":"Robbins CJ, Bates KM, Rimm DL. HER2 testing: evolution and update for a companion diagnostic assay. Nat Rev Clin Oncol. 2025;22:408\u201323. https:\/\/doi.org\/10.1038\/s41571-025-01016-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"1843_CR70","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","volume":"31","author":"Y Yin","year":"2025","unstructured":"Yin Y, Fan Y, Ouyang Q, Song L, Wang X, Li W, et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2025;31:1969\u201375. https:\/\/doi.org\/10.1038\/s41591-025-03630-w.","journal-title":"Nat Med"},{"key":"1843_CR71","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1038\/s41591-025-03638-2","volume":"31","author":"S Zhao","year":"2025","unstructured":"Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, et al. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials. Nat Med. 2025;31:1976\u201386. https:\/\/doi.org\/10.1038\/s41591-025-03638-2.","journal-title":"Nat Med"},{"key":"1843_CR72","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1038\/s41591-025-03883-5","volume":"31","author":"S Hong","year":"2025","unstructured":"Hong S, Wang Q, Cheng Y, Luo Y, Qu X, Zhu H, et al. First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. Nat Med. 2025;31:3654\u201361. https:\/\/doi.org\/10.1038\/s41591-025-03883-5.","journal-title":"Nat Med"},{"key":"1843_CR73","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1038\/s41591-024-03266-2","volume":"30","author":"K Khoury","year":"2024","unstructured":"Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, et al. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024;30:3728\u201336. https:\/\/doi.org\/10.1038\/s41591-024-03266-2.","journal-title":"Nat Med"},{"key":"1843_CR74","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","volume":"30","author":"RA Shatsky","year":"2024","unstructured":"Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, et al. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024;30:3737\u201347. https:\/\/doi.org\/10.1038\/s41591-024-03267-1.","journal-title":"Nat Med"},{"key":"1843_CR75","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.ccell.2026.03.017","volume":"44","author":"D Planchard","year":"2026","unstructured":"Planchard D, Cozic N, Mosele MF, Corcos N, Le BL, Pradat Y, et al. Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study. Cancer Cell. 2026;44:1147\u2013e11596. https:\/\/doi.org\/10.1016\/j.ccell.2026.03.017.","journal-title":"Cancer Cell"},{"key":"1843_CR76","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","volume":"31","author":"J Liu","year":"2025","unstructured":"Liu J, Yang J, Sun Y, Gong J, Yue J, Pan Y, et al. CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat Med. 2025;31:3028\u201336. https:\/\/doi.org\/10.1038\/s41591-025-03783-8.","journal-title":"Nat Med"},{"key":"1843_CR77","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","volume":"31","author":"DY Ruan","year":"2025","unstructured":"Ruan DY, Wu HX, Luo SX, Huang WW, Liang XJ, Niu ZX, et al. The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial. Nat Med. 2025;31:3037\u201346. https:\/\/doi.org\/10.1038\/s41591-025-03781-w.","journal-title":"Nat Med"},{"key":"1843_CR78","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"DY Ruan","year":"2025","unstructured":"Ruan DY, Liu FR, Wei XL, Luo SX, Zhuang ZX, Wang ZN, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025;26:227\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(24)00636-3.","journal-title":"Lancet Oncol"},{"key":"1843_CR79","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","volume":"31","author":"Y Ma","year":"2025","unstructured":"Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng X, et al. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial. Nat Med. 2025;31:1949\u201357. https:\/\/doi.org\/10.1038\/s41591-025-03600-2.","journal-title":"Nat Med"},{"key":"1843_CR80","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(25)00733-8","volume":"27","author":"ML Johnson","year":"2026","unstructured":"Johnson ML, Patel MR, Falchook GS, Koyama T, Gutierrez M, Awad MM, et al. Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1\/2 trial. Lancet Oncol. 2026;27:491\u2013501. https:\/\/doi.org\/10.1016\/S1470-2045(25)00733-8.","journal-title":"Lancet Oncol"},{"key":"1843_CR81","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccell.2026.02.006","volume":"44","author":"J Duan","year":"2026","unstructured":"Duan J, Sun Y, Wang Q, Xing L, Wu L, Han L, et al. HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a\/b trial. Cancer Cell. 2026;44:846\u2013e8573. https:\/\/doi.org\/10.1016\/j.ccell.2026.02.006.","journal-title":"Cancer Cell"},{"key":"1843_CR82","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(25)00465-6","volume":"26","author":"T Fuereder","year":"2025","unstructured":"Fuereder T, Garde-Noguera J, Garcia-Mosquera JJ, Ruiz-Borrego M, Valero M, Llombart-Cussac A, et al. Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025;26:1454\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(25)00465-6.","journal-title":"Lancet Oncol"},{"key":"1843_CR83","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S1470-2045(25)00470-X","volume":"26","author":"R Bartsch","year":"2025","unstructured":"Bartsch R, Marhold M, Garde-Noguera J, Gion M, Ruiz-Borrego M, Greil R, et al. Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025;26:1467\u201378. https:\/\/doi.org\/10.1016\/S1470-2045(25)00470-X.","journal-title":"Lancet Oncol"},{"key":"1843_CR84","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1038\/s41591-025-03744-1","volume":"31","author":"M Preusser","year":"2025","unstructured":"Preusser M, Garde-Noguera J, Garcia-Mosquera JJ, Gion M, Greil R, Arumi M, et al. Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial. Nat Med. 2025;31:2797\u2013805. https:\/\/doi.org\/10.1038\/s41591-025-03744-1.","journal-title":"Nat Med"},{"key":"1843_CR85","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1038\/s41591-025-03885-3","volume":"31","author":"B Pistilli","year":"2025","unstructured":"Pistilli B, Mosele F, Corcos N, Pierotti L, Pradat Y, Le BL, et al. Patritumab deruxtecan in HR(+)HER2(-) advanced breast cancer: a phase 2 trial. Nat Med. 2025;31:3492\u2013503. https:\/\/doi.org\/10.1038\/s41591-025-03885-3.","journal-title":"Nat Med"},{"key":"1843_CR86","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1038\/s41591-025-03843-z","volume":"31","author":"S Kopetz","year":"2025","unstructured":"Kopetz S, Boni V, Kato K, Raghav KPS, Vieito M, Pallis A, et al. Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial. Nat Med. 2025;31:3504\u201313. https:\/\/doi.org\/10.1038\/s41591-025-03843-z.","journal-title":"Nat Med"},{"key":"1843_CR87","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1038\/s41591-025-03792-7","volume":"31","author":"C Liu","year":"2025","unstructured":"Liu C, Liu D, Ji Y, Sun M, Gao S, Ma X, et al. A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2025;31:3485\u201391. https:\/\/doi.org\/10.1038\/s41591-025-03792-7.","journal-title":"Nat Med"},{"key":"1843_CR88","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang Y, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024;25:901\u201311. https:\/\/doi.org\/10.1016\/S1470-2045(24)00159-1.","journal-title":"Lancet Oncol"},{"key":"1843_CR89","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21:203\u201323. https:\/\/doi.org\/10.1038\/s41571-023-00850-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"1843_CR90","doi-asserted-by":"publisher","first-page":"100849","DOI":"10.1016\/j.medj.2025.100849","volume":"6","author":"X Zhou","year":"2025","unstructured":"Zhou X, Han Y, Fang Y, Ma P, Zhou J, Jiang Y, et al. Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy. Med. 2025;6:100849. https:\/\/doi.org\/10.1016\/j.medj.2025.100849.","journal-title":"Med"},{"key":"1843_CR91","doi-asserted-by":"publisher","first-page":"101929","DOI":"10.1016\/j.xcrm.2025.101929","volume":"6","author":"SY Oh","year":"2025","unstructured":"Oh SY, Park S, Lee S, Lee EJ, Kim TH, Choi SJ, et al. The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. Cell Rep Med. 2025;6:101929. https:\/\/doi.org\/10.1016\/j.xcrm.2025.101929.","journal-title":"Cell Rep Med"},{"key":"1843_CR92","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","volume":"22","author":"F Zhou","year":"2025","unstructured":"Zhou F, Guo H, Xia Y, Le X, Tan DSW, Ramalingam SS, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol. 2025;22:95\u2013116. https:\/\/doi.org\/10.1038\/s41571-024-00971-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"1843_CR93","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41571-025-01051-9","volume":"22","author":"JB Lee","year":"2025","unstructured":"Lee JB, Shim JS, Cho BC. Evolving roles of MET as a therapeutic target in NSCLC and beyond. Nat Rev Clin Oncol. 2025;22:640\u201366. https:\/\/doi.org\/10.1038\/s41571-025-01051-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"1843_CR94","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41591-024-03007-5","volume":"30","author":"X Gao","year":"2024","unstructured":"Gao X, Ji K, Jia Y, Shan F, Chen Y, Xu N, et al. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b\/2 COMPASSION-04 trial. Nat Med. 2024;30:1943\u201351. https:\/\/doi.org\/10.1038\/s41591-024-03007-5.","journal-title":"Nat Med"},{"key":"1843_CR95","doi-asserted-by":"publisher","first-page":"100531","DOI":"10.1016\/j.medj.2024.10.008","volume":"6","author":"B Long","year":"2025","unstructured":"Long B, Zhou H, Yu Z, Zhu J, Yang H, Huang Z, et al. Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric\/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study. Med. 2025;6:100531. https:\/\/doi.org\/10.1016\/j.medj.2024.10.008.","journal-title":"Med"},{"key":"1843_CR96","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1038\/s41591-025-03967-2","volume":"31","author":"GV Long","year":"2025","unstructured":"Long GV, Nair N, Marbach D, Scolyer RA, Wilson S, Cotting D, et al. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b\/2 Morpheus-Melanoma trial. Nat Med. 2025;31:3700\u201312. https:\/\/doi.org\/10.1038\/s41591-025-03967-2.","journal-title":"Nat Med"},{"key":"1843_CR97","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1470-2045(25)00140-8","volume":"26","author":"S Escriva-de-Romani","year":"2025","unstructured":"Escriva-de-Romani S, Cejalvo JM, Alba E, Friedmann J, Rodriguez-Lescure A, Savard MF, et al. Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study. Lancet Oncol. 2025;26:745\u201358. https:\/\/doi.org\/10.1016\/S1470-2045(25)00140-8.","journal-title":"Lancet Oncol"},{"key":"1843_CR98","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41571-025-01035-9","volume":"22","author":"S Zhao","year":"2025","unstructured":"Zhao S, Zhao H, Yang W, Zhang L. The next generation of immunotherapies for lung cancers. Nat Rev Clin Oncol. 2025;22:592\u2013616. https:\/\/doi.org\/10.1038\/s41571-025-01035-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"1843_CR99","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41571-024-00914-x","volume":"21","author":"T Sen","year":"2024","unstructured":"Sen T, Takahashi N, Chakraborty S, Takebe N, Nassar AH, Karim NA, et al. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol. 2024;21:610\u201327. https:\/\/doi.org\/10.1038\/s41571-024-00914-x.","journal-title":"Nat Rev Clin Oncol"},{"key":"1843_CR100","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-025-01690-6","volume":"18","author":"X Zhai","year":"2025","unstructured":"Zhai X, Zhang Z, Chen Y, Wu Y, Zhen C, Liu Y, et al. Current and future therapies for small cell lung carcinoma. J Hematol Oncol. 2025;18:37. https:\/\/doi.org\/10.1186\/s13045-025-01690-6.","journal-title":"J Hematol Oncol"},{"key":"1843_CR101","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.ccell.2024.05.024","volume":"42","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Pan Y, Yang X, Zhao Y, Han G, Pang Q, et al. Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial. Cancer Cell. 2024;42:1258\u2013e12672. https:\/\/doi.org\/10.1016\/j.ccell.2024.05.024.","journal-title":"Cancer Cell"},{"key":"1843_CR102","doi-asserted-by":"publisher","first-page":"102076","DOI":"10.1016\/j.xcrm.2025.102076","volume":"6","author":"JJ Sacco","year":"2025","unstructured":"Sacco JJ, Kirk P, Leach E, Shoushtari AN, Carvajal RD, Britton-Rivet C, et al. Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific. Cell Rep Med. 2025;6:102076. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102076.","journal-title":"Cell Rep Med"},{"key":"1843_CR103","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1182\/blood.2025029909","volume":"146","author":"L Falchi","year":"2025","unstructured":"Falchi L, Sureda A, Leppa S, Vermaat JSP, Nijland M, Christensen JH, et al. Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. Blood. 2025;146:2629\u201340. https:\/\/doi.org\/10.1182\/blood.2025029909.","journal-title":"Blood"},{"key":"1843_CR104","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1182\/blood.2025028863","volume":"146","author":"J Sam","year":"2025","unstructured":"Sam J, Leclercq-Cohen G, Gebhardt S, Surowka M, Herter S, Lechner K, et al. Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma. Blood. 2025;146:1824\u201336. https:\/\/doi.org\/10.1182\/blood.2025028863.","journal-title":"Blood"},{"key":"1843_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04533-0","author":"M Hutchings","year":"2026","unstructured":"Hutchings M, Dickinson M, Gritti G, Carlo-Stella C, Townsend W, Bosch F, et al. Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial. Nat Med [Internet]. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04533-0.","journal-title":"Nat Med [Internet]"},{"key":"1843_CR106","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","volume":"6","author":"WS Kim","year":"2025","unstructured":"Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jazdzewska E, Poon LM, et al. Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer. 2025;6:528\u201339. https:\/\/doi.org\/10.1038\/s43018-025-00921-6.","journal-title":"Nat Cancer"},{"key":"1843_CR107","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1182\/blood.2024027044","volume":"145","author":"MS Topp","year":"2025","unstructured":"Topp MS, Matasar M, Allan JN, Ansell SM, Barnes JA, Arnason JE, et al. Odronextamab monotherapy in R\/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study. Blood. 2025;145:1498\u2013509. https:\/\/doi.org\/10.1182\/blood.2024027044.","journal-title":"Blood"},{"key":"1843_CR108","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2019004701","volume":"136","author":"NL Bartlett","year":"2020","unstructured":"Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136:2401\u20139. https:\/\/doi.org\/10.1182\/blood.2019004701.","journal-title":"Blood"},{"key":"1843_CR109","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1158\/2159-8290.CD-NB2022-0027","volume":"12","author":"An","year":"2022","unstructured":"An, NK-cell Therapy for CD30\u2009+\u2009Lymphomas. Cancer Discov. 2022;12:1401\u20132. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2022-0027.","journal-title":"Cancer Discov"},{"key":"1843_CR110","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","volume":"31","author":"Y Nieto","year":"2025","unstructured":"Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med. 2025;31:1987\u201393. https:\/\/doi.org\/10.1038\/s41591-025-03640-8.","journal-title":"Nat Med"},{"key":"1843_CR111","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2025029546","volume":"147","author":"CS Diefenbach","year":"2026","unstructured":"Diefenbach CS, Jegede O, Wang V, Ansell SM, Kostakoglu L, Steidl C, et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026;147:2041\u201352. https:\/\/doi.org\/10.1182\/blood.2025029546.","journal-title":"Blood"},{"key":"1843_CR112","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1182\/blood.2024024681","volume":"145","author":"HJ Lee","year":"2025","unstructured":"Lee HJ, Ramchandren R, Friedman J, Melear J, Flinn IW, Burke JM, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025;145:290\u20139. https:\/\/doi.org\/10.1182\/blood.2024024681.","journal-title":"Blood"},{"key":"1843_CR113","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood.2025030190","volume":"147","author":"JS Abramson","year":"2026","unstructured":"Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo DE, et al. Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma. Blood. 2026;147:1713\u201322. https:\/\/doi.org\/10.1182\/blood.2025030190.","journal-title":"Blood"},{"key":"1843_CR114","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1182\/blood.2022019536","volume":"143","author":"JW Friedberg","year":"2024","unstructured":"Friedberg JW, Bordoni R, Patel-Donnelly D, Larson T, Goldschmidt J, Boccia R, et al. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. 2024;143:786\u201395. https:\/\/doi.org\/10.1182\/blood.2022019536.","journal-title":"Blood"},{"key":"1843_CR115","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","volume":"22","author":"J Kuruvilla","year":"2021","unstructured":"Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021;22:512\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(21)00005-X.","journal-title":"Lancet Oncol"},{"key":"1843_CR116","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.2019000324","volume":"134","author":"R Chen","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134:1144\u201353. https:\/\/doi.org\/10.1182\/blood.2019000324.","journal-title":"Blood"},{"key":"1843_CR117","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/blood.2024026017","volume":"146","author":"E Mulvey","year":"2025","unstructured":"Mulvey E, Rutherford SC, Leonard JP. The future of follicular lymphoma management: strategies on the horizon. Blood. 2025;146:1792\u2013801. https:\/\/doi.org\/10.1182\/blood.2024026017.","journal-title":"Blood"},{"key":"1843_CR118","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1182\/blood.2024026018","volume":"146","author":"C Casulo","year":"2025","unstructured":"Casulo C, Sehn LH. Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy? Blood. 2025;146:1782\u201391. https:\/\/doi.org\/10.1182\/blood.2024026018.","journal-title":"Blood"},{"key":"1843_CR119","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023022353","volume":"145","author":"E Silkenstedt","year":"2025","unstructured":"Silkenstedt E, Dreyling M. Treatment of relapsed\/refractory MCL. Blood. 2025;145:673\u201382. https:\/\/doi.org\/10.1182\/blood.2023022353.","journal-title":"Blood"},{"key":"1843_CR120","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41375-026-02942-1","volume":"40","author":"R Tavarozzi","year":"2026","unstructured":"Tavarozzi R, Maher N, Catania G, Zacchi G, D\u2019Andrea F, Sofia A, et al. Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions. Leukemia. 2026;40:857\u201371. https:\/\/doi.org\/10.1038\/s41375-026-02942-1.","journal-title":"Leukemia"},{"key":"1843_CR121","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S1470-2045(26)00086-0","volume":"27","author":"Y Zhu","year":"2026","unstructured":"Zhu Y, Liu K, Rosen ST, Liu W, Zhu H. Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials. Lancet Oncol. 2026;27:893\u2013902. https:\/\/doi.org\/10.1016\/S1470-2045(26)00086-0.","journal-title":"Lancet Oncol"},{"key":"1843_CR122","doi-asserted-by":"publisher","unstructured":"Maschmeyer G, De GJ, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2019;33:844\u201362. https:\/\/doi.org\/10.1038\/s41375-019-0388-x.","DOI":"10.1038\/s41375-019-0388-x"},{"key":"1843_CR123","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1182\/blood.2024024788","volume":"145","author":"DS Wallace","year":"2025","unstructured":"Wallace DS, Loh KP, Casulo C. How I treat older patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2025;145:277\u201389. https:\/\/doi.org\/10.1182\/blood.2024024788.","journal-title":"Blood"},{"key":"1843_CR124","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2023023616","volume":"144","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, et al. Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024;144:2375\u201388. https:\/\/doi.org\/10.1182\/blood.2023023616.","journal-title":"Blood"},{"key":"1843_CR125","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1038\/s41591-026-04471-x","volume":"32","author":"MS Raab","year":"2026","unstructured":"Raab MS, Weinhold N, Kortum KM, Kronke J, Fenk R, Weisel K, et al. Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial. Nat Med. 2026;32:2440\u20138. https:\/\/doi.org\/10.1038\/s41591-026-04471-x.","journal-title":"Nat Med"},{"key":"1843_CR126","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41375-025-02841-x","volume":"40","author":"N Bar","year":"2026","unstructured":"Bar N, Martin T, Hofmeister CC, Mateos MV, Hansson M, Paris L, et al. Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study. Leukemia. 2026;40:481\u201390. https:\/\/doi.org\/10.1038\/s41375-025-02841-x.","journal-title":"Leukemia"},{"key":"1843_CR127","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.2025032044","volume":"148","author":"HC Lee","year":"2026","unstructured":"Lee HC, Plattel WJ, Harrison SJ, Sborov DW, Lentzsch S, Spencer A, et al. A phase 1\/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed\/refractory multiple myeloma. Blood. 2026;148:199\u2013212. https:\/\/doi.org\/10.1182\/blood.2025032044.","journal-title":"Blood"},{"key":"1843_CR128","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang CH, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther. 2025;10:227. https:\/\/doi.org\/10.1038\/s41392-025-02280-1.","journal-title":"Signal Transduct Target Ther"},{"key":"1843_CR129","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood.2024025987","volume":"145","author":"J Eckmann","year":"2025","unstructured":"Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I, et al. Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2\u2009+\u20091 format, for the treatment of multiple myeloma. Blood. 2025;145:202\u201319. https:\/\/doi.org\/10.1182\/blood.2024025987.","journal-title":"Blood"},{"key":"1843_CR130","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/blood.2025032536","volume":"147","author":"DN van de Sonneveld","year":"2026","unstructured":"van de Sonneveld DN, Einsele P. Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape. Blood. 2026;147:2176\u201393. https:\/\/doi.org\/10.1182\/blood.2025032536.","journal-title":"Blood"},{"key":"1843_CR131","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-025-01713-2","volume":"18","author":"H Yao","year":"2025","unstructured":"Yao H, Ren SH, Wang LH, Ren MQ, Cai J, Chen D, et al. BCMA\/GPRC5D bispecific CAR T-cell therapy for relapsed\/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial. J Hematol Oncol. 2025;18:56. https:\/\/doi.org\/10.1186\/s13045-025-01713-2.","journal-title":"J Hematol Oncol"},{"key":"1843_CR132","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.2019004537","volume":"136","author":"C Perez","year":"2020","unstructured":"Perez C, Botta C, Zabaleta A, Puig N, Cedena MT, Goicoechea I, et al. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood. 2020;136:199\u2013209. https:\/\/doi.org\/10.1182\/blood.2019004537.","journal-title":"Blood"},{"key":"1843_CR133","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41568-024-00755-x","volume":"24","author":"DSD Cordas","year":"2024","unstructured":"Cordas DSD, Toenges R, Bertamini L, Alberge JB, Ghobrial IM. New horizons in our understanding of precursor multiple myeloma and early interception. Nat Rev Cancer. 2024;24:867\u201386. https:\/\/doi.org\/10.1038\/s41568-024-00755-x.","journal-title":"Nat Rev Cancer"},{"key":"1843_CR134","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"ME Goebeler","year":"2020","unstructured":"Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol. 2020;17:418\u201334. https:\/\/doi.org\/10.1038\/s41571-020-0347-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"1843_CR135","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-025-01775-2","volume":"19","author":"E Cousin","year":"2026","unstructured":"Cousin E, Picard A, Oundjian M, Tardif N, Quemener A, Rio AG, et al. Molecularly targeted therapy and immunotherapy in leukemias. J Hematol Oncol. 2026;19:12. https:\/\/doi.org\/10.1186\/s13045-025-01775-2.","journal-title":"J Hematol Oncol"},{"key":"1843_CR136","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1182\/blood.2023022921","volume":"145","author":"T Badar","year":"2025","unstructured":"Badar T, Luger SM, Litzow MR. Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2025;145:1475\u201384. https:\/\/doi.org\/10.1182\/blood.2023022921.","journal-title":"Blood"},{"key":"1843_CR137","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1182\/blood.2024027500","volume":"145","author":"R Bassan","year":"2025","unstructured":"Bassan R, Chiaretti S, Della SI, Santoro A, Spinelli O, Tosi M, et al. Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study. Blood. 2025;145:2447\u201359. https:\/\/doi.org\/10.1182\/blood.2024027500.","journal-title":"Blood"},{"key":"1843_CR138","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood.2026033309","volume":"148","author":"N Boissel","year":"2026","unstructured":"Boissel N, Huguet F, Leguay T, Hunault M, Kim R, Hicheri Y, et al. Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014\/B-QUEST study. Blood. 2026;148:289\u201399. https:\/\/doi.org\/10.1182\/blood.2026033309.","journal-title":"Blood"},{"key":"1843_CR139","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-024-01597-8","volume":"17","author":"J Lu","year":"2024","unstructured":"Lu J, Qiu H, Wang Y, Zhou X, Dai H, Lu X, et al. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial. J Hematol Oncol. 2024;17:79. https:\/\/doi.org\/10.1186\/s13045-024-01597-8.","journal-title":"J Hematol Oncol"},{"key":"1843_CR140","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-025-01709-y","volume":"18","author":"NJ Short","year":"2025","unstructured":"Short NJ, Kantarjian H, Furudate K, Jain N, Ravandi F, Karrar O, et al. Molecular characterization and predictors of relapse in patients with Ph\u2009+\u2009ALL after frontline ponatinib and blinatumomab. J Hematol Oncol. 2025;18:55. https:\/\/doi.org\/10.1186\/s13045-025-01709-y.","journal-title":"J Hematol Oncol"},{"key":"1843_CR141","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41375-025-02855-5","volume":"40","author":"M Ansuinelli","year":"2026","unstructured":"Ansuinelli M, Peragine N, De PM, Puzzolo MC, Di TM, Elia L, et al. Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia. Leukemia. 2026;40:577\u201386. https:\/\/doi.org\/10.1038\/s41375-025-02855-5.","journal-title":"Leukemia"},{"key":"1843_CR142","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","volume":"16","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, et al. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023;16:22. https:\/\/doi.org\/10.1186\/s13045-023-01409-5.","journal-title":"J Hematol Oncol"},{"key":"1843_CR143","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N Gokbuget","year":"2018","unstructured":"Gokbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331. https:\/\/doi.org\/10.1182\/blood-2017-08-798322.","journal-title":"Blood"},{"key":"1843_CR144","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1182\/blood-2017-09-804658","volume":"131","author":"MS Topp","year":"2018","unstructured":"Topp MS, Zimmerman Z, Cannell P, Dombret H, Maertens J, Stein A, et al. Health-related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood. 2018;131:2906\u201314. https:\/\/doi.org\/10.1182\/blood-2017-09-804658.","journal-title":"Blood"},{"key":"1843_CR145","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/s41375-020-01089-x","volume":"35","author":"AH Wei","year":"2021","unstructured":"Wei AH, Ribera JM, Larson RA, Ritchie D, Ghobadi A, Chen Y, et al. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021;35:2220\u201331. https:\/\/doi.org\/10.1038\/s41375-020-01089-x.","journal-title":"Leukemia"},{"key":"1843_CR146","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1182\/blood.2024024517","volume":"145","author":"AJ Lamble","year":"2025","unstructured":"Lamble AJ, Kovach AE, Shah NN. How I treat postimmunotherapy relapsed B-ALL. Blood. 2025;145:64\u201374. https:\/\/doi.org\/10.1182\/blood.2024024517.","journal-title":"Blood"},{"key":"1843_CR147","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41375-026-02962-x","volume":"40","author":"N Lertvivatpong","year":"2026","unstructured":"Lertvivatpong N, Inaba H. Blinatumomab in pediatric acute lymphoblastic leukemia: current and future use. Leukemia. 2026;40:1352\u201363. https:\/\/doi.org\/10.1038\/s41375-026-02962-x.","journal-title":"Leukemia"},{"key":"1843_CR148","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13045-024-01552-7","volume":"17","author":"NJ Short","year":"2024","unstructured":"Short NJ, Jabbour E, Jain N, Kantarjian H. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions. J Hematol Oncol. 2024;17:32. https:\/\/doi.org\/10.1186\/s13045-024-01552-7.","journal-title":"J Hematol Oncol"},{"key":"1843_CR149","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1182\/blood.2020007848","volume":"137","author":"E Brivio","year":"2021","unstructured":"Brivio E, Locatelli F, Lopez-Yurda M, Malone A, Diaz-de-Heredia C, Bielorai B, et al. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood. 2021;137:1582\u201390. https:\/\/doi.org\/10.1182\/blood.2020007848.","journal-title":"Blood"},{"key":"1843_CR150","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/s41375-022-01649-3","volume":"36","author":"PA Thompson","year":"2022","unstructured":"Thompson PA, Jiang X, Banerjee P, Basar R, Garg N, Chen K, et al. A phase two study of high dose blinatumomab in Richter\u2019s syndrome. Leukemia. 2022;36:2228\u201332. https:\/\/doi.org\/10.1038\/s41375-022-01649-3.","journal-title":"Leukemia"},{"key":"1843_CR151","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1182\/blood.2024024893","volume":"146","author":"BT Grainger","year":"2025","unstructured":"Grainger BT, Thompson PA, Cheah CY. Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia. Blood. 2025;146:145\u201354. https:\/\/doi.org\/10.1182\/blood.2024024893.","journal-title":"Blood"},{"key":"1843_CR152","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood.2024025482","volume":"146","author":"M Shadman","year":"2025","unstructured":"Shadman M, Davids MS. How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor. Blood. 2025;146:2029\u201336. https:\/\/doi.org\/10.1182\/blood.2024025482.","journal-title":"Blood"},{"key":"1843_CR153","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","volume":"16","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo A, Alvarez-Vallina L, Sanz L. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol. 2023;16:83. https:\/\/doi.org\/10.1186\/s13045-023-01482-w.","journal-title":"J Hematol Oncol"},{"key":"1843_CR154","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41591-026-04238-4","volume":"32","author":"C Dusing","year":"2026","unstructured":"Dusing C, Gyorfi AH, Stutz AN, Lahu LM, Deicher FS, Li YN, et al. Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases. Nat Med. 2026;32:1530\u201342. https:\/\/doi.org\/10.1038\/s41591-026-04238-4.","journal-title":"Nat Med"},{"key":"1843_CR155","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood.2025031629","volume":"147","author":"E Terpos","year":"2026","unstructured":"Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Kanellias N, et al. Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma. Blood. 2026;147:1574\u201383. https:\/\/doi.org\/10.1182\/blood.2025031629.","journal-title":"Blood"},{"key":"1843_CR156","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/blood.2025028848","volume":"147","author":"C Thompson","year":"2026","unstructured":"Thompson C, Trneny M, Morschhauser F, Salles G, Reagan PM, Hertzberg M, et al. PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study. Blood. 2026;147:254\u201365. https:\/\/doi.org\/10.1182\/blood.2025028848.","journal-title":"Blood"},{"key":"1843_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04452-0","author":"LA Byers","year":"2026","unstructured":"Byers LA, Cho BC, Cooper AJ, Chiang AC, Han JY, Furqan M, et al. SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. Nat Med [Internet]. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04452-0.","journal-title":"Nat Med [Internet]"},{"key":"1843_CR158","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","volume":"39","author":"L Pagano","year":"2025","unstructured":"Pagano L, Maschmeyer G, Lamoth F, Blennow O, Xhaard A, Spadea M, et al. Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2025;39:1547\u201357. https:\/\/doi.org\/10.1038\/s41375-025-02586-7.","journal-title":"Leukemia"},{"key":"1843_CR159","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S1470-2045(25)00330-4","volume":"26","author":"V Hungria","year":"2025","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26:1067\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(25)00330-4.","journal-title":"Lancet Oncol"},{"key":"1843_CR160","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood.2020009806","volume":"137","author":"EJ Lowe","year":"2021","unstructured":"Lowe EJ, Reilly AF, Lim MS, Gross TG, Saguilig L, Barkauskas DA, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137:3595\u2013603. https:\/\/doi.org\/10.1182\/blood.2020009806.","journal-title":"Blood"},{"key":"1843_CR161","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327\u201344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8.","journal-title":"Nat Rev Clin Oncol"},{"key":"1843_CR162","doi-asserted-by":"publisher","first-page":"102742","DOI":"10.1016\/j.xcrm.2026.102742","volume":"7","author":"NA Bili","year":"2026","unstructured":"Bili NA, Damodaran S, Meric-Bernstam F. Antibody-drug conjugates in breast cancer: Progress and future directions. Cell Rep Med. 2026;7:102742. https:\/\/doi.org\/10.1016\/j.xcrm.2026.102742.","journal-title":"Cell Rep Med"},{"key":"1843_CR163","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1038\/s41591-026-04380-z","volume":"32","author":"I Melero","year":"2026","unstructured":"Melero I, Tanos T, Calvo AE, Qvortrup C, van Baraibar DM. Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial. Nat Med. 2026;32:2430\u20139. https:\/\/doi.org\/10.1038\/s41591-026-04380-z.","journal-title":"Nat Med"},{"key":"1843_CR164","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-026-01799-2","volume":"19","author":"N Lu","year":"2026","unstructured":"Lu N, Yan B, Li YQ, Wan JL. Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming. J Hematol Oncol. 2026;19:38. https:\/\/doi.org\/10.1186\/s13045-026-01799-2.","journal-title":"J Hematol Oncol"},{"key":"1843_CR165","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s43018-026-01181-8","volume":"7","author":"P Schmid","year":"2026","unstructured":"Schmid P, Im SA, Nowecki Z, Wysocki PJ, Jassem J, Jung KH, et al. First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b\/2 BEGONIA platform trial. Nat Cancer. 2026;7:983\u201392. https:\/\/doi.org\/10.1038\/s43018-026-01181-8.","journal-title":"Nat Cancer"},{"key":"1843_CR166","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(25)00158-5","volume":"26","author":"S Gupta","year":"2025","unstructured":"Gupta S, Loriot Y, Van der Bedke HM, Valderrama J, Kikuchi BP. Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2025;26:795\u2013805. https:\/\/doi.org\/10.1016\/S1470-2045(25)00158-5.","journal-title":"Lancet Oncol"},{"key":"1843_CR167","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1038\/s41591-025-03746-z","volume":"31","author":"T Cascone","year":"2025","unstructured":"Cascone T, Bonanno L, Guisier F, Insa A, Liberman M, Bylicki O, et al. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial. Nat Med. 2025;31:2788\u201396. https:\/\/doi.org\/10.1038\/s41591-025-03746-z.","journal-title":"Nat Med"},{"key":"1843_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04455-x","author":"M Wermke","year":"2026","unstructured":"Wermke M, Ochsenreither S, Jaeger D, Becker H, Bleckmann A, Bozorgmehr F, et al. MAGE-A4\/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and\/or refractory solid tumors: a phase 1 trial. Nat Med [Internet]. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04455-x.","journal-title":"Nat Med [Internet]"},{"key":"1843_CR169","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","volume":"25","author":"A Zippelius","year":"2025","unstructured":"Zippelius A, Tolaney SM, Tarantino P, Balthasar JP, Thurber GM. Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment. Nat Rev Cancer. 2025;25:925\u201344. https:\/\/doi.org\/10.1038\/s41568-025-00869-w.","journal-title":"Nat Rev Cancer"},{"key":"1843_CR170","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.medj.2026.101104","volume":"7","author":"WC Luo","year":"2026","unstructured":"Luo WC, Zhong SX, Liu SM, Wu YL. NSCLC: Five trials to watch. Med. 2026;7:101104. https:\/\/doi.org\/10.1016\/j.medj.2026.101104.","journal-title":"Med"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01843-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01843-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01843-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:11:52Z","timestamp":1788905512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01843-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":170,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01843-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"2 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"76"}}